INO · Company research
Inovio Pharmaceuticals, Inc. (INO): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
22records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| FDA decision on October 30 looms for Inovio Pharmaceuticals stock - ad-hoc-news.de | FDA decision on October 30 looms for Inovio Pharmaceuticals stock ad-hoc-news.de | View source ↗ | ad-hoc-news.de | Oct 17, 2026 | neutral | 0 | 0.6 |
| INO Oct 2026 1.000 call (INO261030C00001000) Interactive Stock Chart - Yahoo! Finance Canada | INO Oct 2026 1.000 call (INO261030C00001000) Interactive Stock Chart Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 17, 2026 | neutral | 0 | 0.6 |
| INO Jan 2029 1.000 call (INO290119C00001000) Stock Price, News, Quote & History - Yahoo! Finance Canada | INO Jan 2029 1.000 call (INO290119C00001000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 17, 2026 | neutral | 0 | 0.6 |
| INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally - Stocktwits | INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally Stocktwits | View source ↗ | Stocktwits | Oct 16, 2026 | neutral | 0 | 0.6 |
| INO Oct 2026 1.500 put (INO261030P00001500) Stock Historical Prices & Data - Yahoo Finance - Yahoo! Finance Canada | INO Oct 2026 1.500 put (INO261030P00001500) Stock Historical Prices & Data - Yahoo Finance Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| INO Jan 2029 2.000 put (INO290119P00002000) Interactive Stock Chart - Yahoo Finance - Yahoo! Finance Canada | INO Jan 2029 2.000 put (INO290119P00002000) Interactive Stock Chart - Yahoo Finance Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| INO May 2027 1.000 call (INO270521C00001000) Stock Price, News, Quote & History - Yahoo! Finance Canada | INO May 2027 1.000 call (INO270521C00001000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| Inovio Pharmaceuticals, Inc. (INO) Stock Price, News, Quote & History - Yahoo! Finance Canada | Inovio Pharmaceuticals, Inc. (INO) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| Inovio Pharmaceuticals, Inc. (INO) stock price, news, quote and history - Yahoo Finance UK | Inovio Pharmaceuticals, Inc. (INO) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 9, 2026 | neutral | 0 | 0.6 |
| Inovio Pharmaceuticals (INO) Short Interest & Short Float | Updated Oct 2026 $INO - MarketBeat | Inovio Pharmaceuticals (INO) Short Interest & Short Float | Updated Oct 2026 $INO MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer | Pfizer announced FDA approval of Tukysa in combination with Roche's Herceptin and Perjeta for frontline maintenance treatment of HER2-positive breast cancer. The phase III HER2CLIMB-05 study showed Tukysa reduced progression or death risk by 35.9%, with median progression-free survival of 24.9 months versus 16.3 months for placebo. This approval expands Tukysa's use beyond second-line treatment and provides a chemotherapy-free maintenance option. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer | Pfizer announced FDA approval of Tukysa in combination with Roche's Herceptin and Perjeta for frontline maintenance treatment of HER2-positive breast cancer. The phase III HER2CLIMB-05 study showed Tukysa reduced progression or death risk by 35.9%, with median progression-free survival of 24.9 months versus 16.3 months for placebo. This approval expands Tukysa's use beyond second-line treatment and provides a chemotherapy-free maintenance option. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer | Pfizer announced FDA approval of Tukysa in combination with Roche's Herceptin and Perjeta for frontline maintenance treatment of HER2-positive breast cancer. The phase III HER2CLIMB-05 study showed Tukysa reduced progression or death risk by 35.9%, with median progression-free survival of 24.9 months versus 16.3 months for placebo. This approval expands Tukysa's use beyond second-line treatment and provides a chemotherapy-free maintenance option. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| Inovio Stock: The Final Countdown To A Binary FDA Decision (NASDAQ:INO) - Seeking Alpha | Inovio Stock: The Final Countdown To A Binary FDA Decision (NASDAQ:INO) Seeking Alpha | View source ↗ | Seeking Alpha | Aug 25, 2026 | neutral | 0 | 0.6 |
| Inovio Stock Jumps As Jefferies Upgrade Bets On FDA Decision - StocksToTrade | Inovio Stock Jumps As Jefferies Upgrade Bets On FDA Decision StocksToTrade | View source ↗ | StocksToTrade | Aug 16, 2026 | neutral | 0 | 0.6 |
| RA Capital reports 10.67M-share Inovio (NASDAQ: INO) stake capped at 9.99% - Stock Titan | RA Capital reports 10.67M-share Inovio (NASDAQ: INO) stake capped at 9.99% Stock Titan | View source ↗ | Stock Titan | Aug 7, 2026 | neutral | 0 | 0.6 |
| INO: Higher Share Count Will Set Stage For Future Upside Repricing - Simply Wall Street | INO: Higher Share Count Will Set Stage For Future Upside Repricing Simply Wall Street | View source ↗ | Simply Wall Street | Aug 2, 2026 | neutral | 0 | 0.6 |
| Inovio raises USD 20m ahead of make-or-break FDA decision on INO-3107 - AllSci | Inovio raises USD 20m ahead of make-or-break FDA decision on INO-3107 AllSci | View source ↗ | AllSci | Jul 30, 2026 | neutral | 0 | 0.6 |
| INOVIO Announces Pricing of $20.0 Million Public Offering - PR Newswire | INOVIO Announces Pricing of $20.0 Million Public Offering PR Newswire | View source ↗ | PR Newswire | Jul 29, 2026 | neutral | 0 | 0.6 |
| INOVIO Announces Proposed Public Offering - PR Newswire | INOVIO Announces Proposed Public Offering PR Newswire | View source ↗ | PR Newswire | Jul 29, 2026 | neutral | 0 | 0.6 |
| INO Forecast — Price Target — Prediction for 2027 - TradingView | INO Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial - Stocktwits | INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial Stocktwits | View source ↗ | Stocktwits | May 21, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.